DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for myocardial infarction — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMyocardial infarction maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for myocardial infarction is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lipoprotein(a) (LPA) — LPA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TCE · 1.07 Å · ligand (2S)-3-phenyl-2-[(3R)-pyrrolidin-3-yl]propanoic acid (HWF). Experimental structure, not a prediction.
What the evidence adds up to
No drug is tested or proposed for repurposing in these abstracts. The 2013 review states that the molecular mechanisms of myocardial infarction remain unknown and that altered gene expression may play a role, but it offers no specific prognostic markers or therapeutic targets. The 2017 review similarly calls the search for new molecular targets a priority, noting that despite improvements in pharmacological treatment, the social and economic burden of cardiovascular disease is expected to increase. The 2018 bioinformatics study identifies protein complexes that may be related to myocardial infarction, but it explicitly says these complexes "may" be involved and that the findings are based on computational inference, not experimental validation.
No concrete numbers — survival, response rates, or sample sizes — appear in any of these abstracts. The 2013 paper is a review of transcriptome analysis methods, not a clinical or preclinical trial. The 2017 paper is a general review of drug targets with no specific drug named. The 2018 paper is a computational analysis that identifies candidate protein complexes but does not test any intervention. All three papers are hypothesis-generating, not hypothesis-testing.
What is still missing is any clinical or preclinical evidence that a specific drug alters the course of myocardial infarction. These abstracts do not report a trial, a patient cohort, or a measurable outcome. The field lacks validated molecular targets, funded clinical trials of repurposed drugs, and patient stratification strategies that could move beyond computational predictions.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Genomics · 2013 · 10 citations · open access
Will Global Transcriptome Analysis Allow the Detection of Novel Prognostic Markers in Coronary Artery Disease and Heart Failure?
AbstractCoronary artery disease (CAD) is one of the leading causes of death in the developed countries. Myocardial infarction (MI) is an acute episode of CAD that results in myocardial injury and subsequent heart failure (HF). In the acute phase of MI several risk factors for future cardiovascular events have been found. The molecular mechanisms of these disorders are still unknown, but altered gene expression may play an important role in the development and progression of cardiovascular diseases. High-throughput techniques should greatly facilitate the elucidation of the mechanisms and provide novel insights into the pathophysiology of cardiovascular diseases. In this review we focus on the perspectives of gene-expression profiling conducted on cardiac tissues and blood for the determination of novel diagnostic and prognostic markers and therapeutic targets.
Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · 2017 · 1 citations
Novel Drug Targets for the Treatment of Cardiac Diseases
AbstractBackground: Cardiovascular disease is the leading cause of morbidity and mortality worldwide in developed countries, and its social and economic burden is expected to increase dramatically over the next decades. Despite significative improvement in the pharmacological treatment, and the huge advances in prevention, the quest for new molecular targets and for novel, more efficient and personalized therapies is still a priority for this group of pathologies. Keywords: Cardiovascular disease, coronary artery disease, heart failure, myocardial infarction, drug discovery, drug targets.
Molecular Medicine Reports · 2018 · 1 citations · open access
Identification of protein complexes associated with myocardial infarction using a bioinformatics approach
AbstractMyocardial infarction (MI) is a leading cause of mortality and disability worldwide. Determination of the molecular mechanisms underlying the disease is crucial for identifying possible therapeutic targets and designing effective treatments. On the basis that MI may be caused by dysfunctional protein complexes rather than single genes, the present study aimed to use a bioinformatics approach to identifying complexes that may serve important roles in the development of MI. By investigating the proteins involved in these identified complexes, numerous proteins have been reported that are related to MI, whereas other proteins interacted with MI‑related proteins, which implied that these protein complexes may indeed be related to the development of MI. The protein complexes detected in the present study may aid in our understanding of the molecular mechanisms that underlie MI pathogenesis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
